Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma DOI Creative Commons
Sanika Suvarnapathaki,

Antolin Serrano-Farias,

Jonathan C. Dudley

и другие.

Life, Год журнала: 2024, Номер 14(10), С. 1312 - 1312

Опубликована: Окт. 16, 2024

Using microRNAs (miRNAs) as potential circulating biomarkers in diagnosing and treating glioblastoma (GBM) has garnered a lot of scientific clinical impetus the past decade. As an aggressive primary brain tumor, GBM poses challenges early detection effective treatment with significant current diagnostic constraints limited therapeutic strategies. MiRNA dysregulation is present GBM. The intricate involvement miRNAs altering cell proliferation, invasion, immune escape makes them prospective candidates for identifying monitoring diagnosis response to treatment. These could play dual role, acting both markers targets therapy. By modulating activity various oncogenic tumor-suppressive proteins, create opportunities precision medicine targeted therapies This review centers on critical role function miRNA It highlights their significance providing insights into disease progression, aiding diagnosis, use novel interventions. Ultimately, study would contribute improving patient outcomes challenging landscape management.

Язык: Английский

Radiogenomics and machine learning predict oncogenic signaling pathways in glioblastoma DOI Creative Commons
Abdul Basit Ahanger, Syed Wajid Aalam, Tariq Masoodi

и другие.

Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Янв. 27, 2025

Язык: Английский

Процитировано

1
Immune Cell-NSPC Interactions: Friend or Foe in CNS Injury and Repair? DOI
Chih‐Wei Zeng

Differentiation, Год журнала: 2025, Номер 143, С. 100855 - 100855

Опубликована: Март 15, 2025

Язык: Английский

Процитировано

1
Shrinking the battlefield in cancer therapy: Nanotechnology against cancer stem cells DOI Creative Commons
Queenie Fernandes,

Lubna Therachiyil,

Abdul Quaiyoom Khan

и другие.

European Journal of Pharmaceutical Sciences, Год журнала: 2023, Номер 191, С. 106586 - 106586

Опубликована: Сен. 19, 2023

Cancer remains one of the leading causes mortality worldwide, presenting a significant healthcare challenge owing to limited efficacy current treatments. The application nanotechnology in cancer treatment leverages unique optical, magnetic, and electrical attributes nanomaterials engineer innovative, targeted therapies. Specifically, manipulating allows for enhanced drug loading efficiency, improved bioavailability, delivery systems, reducing non-specific cytotoxic effects characteristic conventional chemotherapies. Furthermore, recent advances have demonstrated encouraging results specifically targeting CSCs, key development considering role these cells disease recurrence resistance treatment. Despite breakthroughs, clinical approval rates nano-drugs not kept pace with research advances, pointing existing obstacles that must be addressed. In conclusion, presents novel, powerful tool fight against cancer, particularly elusive treatment-resistant CSCs. This comprehensive review delves into intricacies nanotherapy, explicitly stem cells, their markers, associated signaling pathways.

Язык: Английский

Процитировано

14
Cellular Aging and Senescence in Cancer: A Holistic Review of Cellular Fate Determinants DOI Creative Commons
Muhammad Tufail, Yuqi Huang,

Jia-Ju Hu

и другие.

Aging and Disease, Год журнала: 2024, Номер unknown, С. 0 - 0

Опубликована: Янв. 1, 2024

This comprehensive review navigates the complex relationship between cellular aging, senescence, and cancer, unraveling determinants of fate. Beginning with an overview aging's significance in explores processes, changes, molecular pathways influencing senescence. The senescence as a dual mechanism acting suppressor contributor, focusing on its impact therapy response. highlights opportunities for cancer therapies that target further examines senescence-associated secretory phenotype strategies to modulate aging influence tumor behavior. Additionally, mechanisms escape cells, emphasizing their prognosis resistance therapy. article addresses current advances, unexplored aspects, future perspectives understanding cancer.

Язык: Английский

Процитировано

4
The dual role of POSTN in maintaining glioblastoma stem cells and the immunosuppressive phenotype of microglia in glioblastoma DOI Creative Commons
Hao Wang, Lin Yao, Jinming Chen

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)

Опубликована: Сен. 4, 2024

Язык: Английский

Процитировано

4
Synthesis and exploration of anticancer potential of spirocyclic 1,2,3-triazoline and aziridine derivatives of natural eudesmanolide isoalantolactone DOI
Sergey S. Patrushev,

Daria O Kichkina,

Arseny D. Moralev

и другие.

Bioorganic Chemistry, Год журнала: 2025, Номер 155, С. 108124 - 108124

Опубликована: Янв. 6, 2025

Язык: Английский

Процитировано

0
Decoding the Role of Kinesin Superfamily Proteins in Glioma Progression DOI

Mohamed J. Saadh,

Zahraa Sabah Ghnim,

Morug Salih Mahdi

и другие.

Journal of Molecular Neuroscience, Год журнала: 2025, Номер 75(1)

Опубликована: Янв. 23, 2025

Язык: Английский

Процитировано

0
Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma DOI Creative Commons
Doina Manu, Rodica Bălașa, Lavinia-Lorena Pruteanu

и другие.

PLoS ONE, Год журнала: 2025, Номер 20(3), С. e0315890 - e0315890

Опубликована: Март 19, 2025

Glioblastoma (GBM), a primary brain tumor, exhibits intratumoral heterogeneity and dynamic spatial-temporal changes. GBM-derived extracellular vesicles (EVs), reflecting tumor characteristics, present potential as liquid-biopsy markers for early diagnosis monitoring. This study aims to evaluate molecular signatures of plasma-derived EVs from GBM patients using conventional flow cytometer. have been isolated glioma healthy controls (HCs) plasma density gradient ultracentrifugation (DGU). were evaluated by bead-based multiplex analysis in Principal component (PCA), hierarchical clustering, correlation provided comprehensive insights into EV characteristics. successfully visualized transmission scanning electron microscopy (STEM). Bead-based cytometer detected the level 37 surface markers, including tumor-related, cancer stem cell, endothelial immune cell- specific antigens. PCA identified that are most significant differentiating subjects, clustering revealed four distinct clusters based on marker levels. signature demonstrated considerable across patient clusters. The presence CD29 emerged not only defining factor cluster patients, but also served differentiate HCs.

Язык: Английский

Процитировано

0
IN SILICO STUDIES AND CYTOTOXICITY ASSAY OF BENZYLIDENE BENZO HYDRAZIDE DERIVATIVES ON CANCER STEM CELL DOI Open Access
Imanuel Gauru,

Yusuf Syahril Alam,

Mardi Santoso

и другие.

International Journal of Applied Pharmaceutics, Год журнала: 2025, Номер unknown, С. 134 - 141

Опубликована: Март 7, 2025

Objective: This study aimed to evaluate the biological activity of benzylidene benzohydrazide derivatives against Cancer Stem Cells (CSCs) through in vitro cytotoxicity tests and silico analyses using molecular docking. Methods: Four hydrazone compounds, namely benzo hydrazide (L1), 2-methyl (L2), 2-nitro (L3), 2-bromobenzylidene (L4) were used for studies. The interaction between compounds EGFR protein receptor (PDB ID: 1m17) was investigated AutoDock tools 1.5.7. PASS server predicted activities substances. ADMET assessed ADMETLab 2.0. Meanwhile, cytotoxic test on CSCs evaluated MTT Assay method. Results: results docking analysis L1-L4 provide binding energy values ranging from -6.69 to-7.74 kcal/mol. value is lower than reference Doxorubicin (-4.30 Kcal/mol). with IC50 L1 0.220±0.360 μg/ml, L2 0.034±0.023 L3 0.355±0.276 L4 1.193±1.122 μg/ml 0.220±0.180 μg/ml. These indicate that have potential be inhibitor. Conclusion: (L2) had as a inhibitor vigorous cell lines

Язык: Английский

Процитировано

0
TRPM7 transactivates the FOSL1 gene through STAT3 and enhances glioma stemness DOI Creative Commons
Shanchun Guo, Ramar Vanajothi, Alyssa A. Guo

и другие.

Cellular and Molecular Life Sciences, Год журнала: 2023, Номер 80(9)

Опубликована: Авг. 29, 2023

We previously reported that TRPM7 regulates glioma cells' stemness through STAT3. In addition, we demonstrated FOSL1 is a response gene for TRPM7, and the serves as an oncogene to promote proliferation invasion.In present study, determined effects of on stem cell (GSC) markers CD133 ALDH1 by flow cytometry, maintenance activity extreme limiting dilution assays (ELDA). To further gain insight into mechanism which activates transcription contribute stemness, constructed promoter its GAS mutants followed luciferase reporter ChIP-qPCR in line patient-derived xenoline. examined GSC well immunohistochemistry staining (IHC) brain tissue microarray (TMA) patients.We revealed knockdown reduces expression ALDH1, required maintain cells. The experiments also showed mutations - 328 336 378 386 elements markedly reduced activity. Constitutively active STAT3 increased while dominant-negative decreased Furthermore, overexpression enhanced silencing STAT3, nuclear lysates cells stimulated constitutively activated can bind two elements, respectively. deacetylation at Lys-116 residue located within DNA binding domain led increase transcriptional found protein associated with grades malignant glioma, correlates patients.These combined results induced activation, mediated action shown be important stemness. These indicated FOSL1, similar diagnostic marker potential drug target patients.

Язык: Английский

Процитировано

10